Improving viral load utilisation to enhance care for Kenyan adolescents with HIV.

Autor:	Dougherty G; ICAP at Columbia University, Mailman School of Public Health, New York, New York, USA gd2410@columbia.edu., Akoth S; ICAP Kenya, Nairobi, Kenya., Hawken M; ICAP Kenya, Nairobi, Kenya., Leting I; ICAP Kenya, Nairobi, Kenya., Mutei R; ICAP Kenya, Nairobi, Kenya., Ngugi C; National AIDS and STI Control Program, Nairobi, Kenya., Naitore D; ICAP Kenya, Nairobi, Kenya., Tsiouris F; ICAP at Columbia University, Mailman School of Public Health, New York, New York, USA., Wakoli A; ICAP Kenya, Nairobi, Kenya., Walker L; ICAP at Columbia University, Mailman School of Public Health, New York, New York, USA., Rabkin M; ICAP at Columbia University, Mailman School of Public Health, New York, New York, USA.; Epidemiology, Columbia University Mailman School of Public Health, New York, New York, USA.
Jazyk:	angličtina
Zdroj:	BMJ open quality [BMJ Open Qual] 2022 Aug; Vol. 11 (3).
DOI:	10.1136/bmjoq-2022-001900
Abstrakt:	Improving the use of viral load (VL) testing for adolescents and young people living with HIV (AYPLWH) is a priority for Kenya's Ministry of Health (MOH). Despite expansion of VL testing coverage and rollout of national policies, guidelines and training, VL result utilisation for AYPLWH remains suboptimal, with inadequate adherence to national guidelines recommending everyone on antiretroviral therapy (ART) with unsuppressed viral load (UVL) (≥401 copies/mL) receive three enhanced adherence counselling (EAC) sessions and a repeat VL test within 3 months. In March 2019, ICAP at Columbia University partnered with the MOH to launch a Quality Improvement Collaborative (QIC) at 22 health facilities in the Eastern Province to optimise management of AYPLWH on ART with UVL. Over 17 months, facility QI teams tested interventions targeting client education, workflow modifications, commodity management, community engagement and improved documentation. The QIC led to marked improvement in the proportion of clients completing three EAC sessions and repeat VL testing. Median completion rate was 16% (n=479) at baseline (from March 2018 to February 2019) and rose to 73% (n=755) during the implementation period (from March 2019 to July 2020). In the final month (July 2020), rates rose to 90% (n=31). Another success was the increase in the proportion of clients whose VL was resuppressed on repeat testing, which improved from 34% (n=273) at baseline to 62% (n=710) during the implementation period and 77% (n=44) in the final month. The QIC also led to improvement in the proportion of AYPLWH on first-line ART whose regimens were switched within 2 months of recorded UVL results, which rose from 58% (n=48) at baseline to 94% (n=128) during the implementation period. In summary, the QIC helped facility teams to identify and prioritise local, contextually appropriate innovations which led to swift improvement in three critical indicators of VL utilisation. Competing Interests: Competing interests: None declared. (© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu